Skip to main content
Premium Trial:

Request an Annual Quote

Neuromuscular Disease Foundation, PerkinElmer Partner on Rare Disease Research

NEW YORK (GenomeWeb) – The Neuromuscular Disease Foundation (NDF) is launching an alliance with PerkinElmer this month to use whole-genome sequencing to investigate the molecular pathways involved in GNE myopathy, a progressive muscle-wasting disease.

GNE myopathy — also known as HIBM — is a rare autosomal recessive condition in which a genetic mutation prevents the generation of sialic acid in cells, leading to muscle dysfunction and degeneration.

In collaboration with PerkinElmer, NDF aims to use sequencing and metabolomics to study 100 patient samples. The partners will also collect their findings into a database to help with patient recruitment for clinical trials. Additional terms of the deal were not disclosed.

"This is one of the first such known efforts made to understand the etiology of a rare disease at the molecular and biochemical level," Madhuri Hegde, vice president and CSO of PerkinElmer Genetics, said in a statement. "We are excited to collaborate with NDF in their efforts for finding an effective therapeutic strategy for HIBM, which will also in turn shape the future approaches for personalized medicine."

PerkinElmer has been working to expand its clinical genomic testing services in recent months, offering whole-exome and whole-genome sequencing for genetic disease diagnostics in newborns and partnering with advocacy groups and foundations focused on specific diseases.